Cure of a patient with profoundly chemotherapy-refractory primary mediastinal large B-cell lymphoma: Role of rituximab, high-dose therapy, and allogeneic stem cell transplantation

Leukemia and Lymphoma

Volumn 46, Issue 7, 2005, Pages 1075-1079

  Nath, Shriram V ^a   Seymour, John F ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Mediastinal large B cell lymphoma; Rituximab; Transplantation

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; AUTOTRANSPLANTATION; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LARGE CELL LYMPHOMA; MEDIASTINUM TUMOR; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL; MEDIASTINAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 22144496868     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500057650     Document Type: Article

References (28)

1. Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Ann Oncol 1999;10:1419-1432.
2. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
3. Rosenwald A, Wright G, Leroy K et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favourable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851-862.
4. Savage KJ, Monti S, Kutok JL et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003;102:3871-3879.
5. van Besien K, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol 2001;19:1855-1864.
6. Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987;316:1493-1498.
7. Popat U, Przepiork D, Champlin R et al. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favourable outcome. J Clin Oncol 1998;16:63-69.
8. Sehn LH, Antin JH, Shulman LN et al. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood 1998;91:717-723.
9. Freytes CO, Loberiza FR, Rizzo JD et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004;104:3797-3803.
10. Peggs KS, MacKinnon S, Linch DC. The role of allogeneic transplantation in non-Hodgkin's lymphoma. Br J Haematol 2005;128:153-168.
11. Escalon MP, Champlin RE, Saliba RM et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004;22:2419-2423.
12. Ratei R, Matylis A, Krahl D et al. Salvage therapy for relapsed mediastinal B-cell lymphoma with allogeneic HLA identical related donor bone marrow transplantation, donor lymphocyte infusion and IDEC-C2B8. Leuk Lymph 2000;40:133-140.
13. Bierman PJ. Allogeneic bone marrow transplantation for lymphoma. Blood Rev 2000;14:1-13.
14. Kewalramani T, Zelenetz AD, Nimer SD et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684-3688.
15. Khouri IF, Romaguera J, Kantarjian H et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998;12:3803-3809.
16. Seymour JF, Grigg AP, Szer J, Fox RM. Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. Ann Oncol 2001;12:1455-1460.
17. Seymour JF, Grigg AP, Szer J, Fox RM. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma. Cancer 2002;94:585-593.
18. Hamlin PA, Zelenetz AD, Kewalramani T et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102:1989-1996.
19. Patti C, Majolino I, Scime R et al. High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas. Eur J Haematol 1993;51:18-24.
20. Khouri IF, Saliba RM, Giralt SA et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001;98:3595-3599.
21. Lazzarino M, Orlandi E, Paulli M et al. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol 1993;11:2306-2313.
22. Hoerr AL, Gao F, Hidalgo J et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2004;22:4561-4566.
23. Culic S, Culic V, Armanda V, Kuljis D, Pesutic-Pisac V, Jankovic S. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl. Pediatr Hematol Oncol 2003;20:339-344.
24. Voudouris D, Sanmugarajah J, Podrumar A, Gruenstein S, Levine RL. Primary mediastinal B cell lymphoma (PMBL) in two sisters. 38th ASCO Annual Meeting; 2002 May 18-21; Orlando. Proc Am Soc Clin Oncol 2002;21:207b (abstract 2646).
25. Vose JM, Anderson JR, Kessinger A et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993;11:1846-1851.
26. Bishop MR. The graft-versus-lymphoma effect: fact, fiction, or opportunity? J Clin Oncol 2003;21:3713-3715.
27. Mollee P, Lazarus HM, Lipton J. Why aren't we performing more allografts for aggressive non-Hodgkin's lymphoma? Bone Marrow Transplant 2003;11:953-960.
28. Robinson SP, Goldstone AH, Mackinnon S et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002;100:4310-4316.